CN1518558B - 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途 - Google Patents

肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途 Download PDF

Info

Publication number
CN1518558B
CN1518558B CN018225993A CN01822599A CN1518558B CN 1518558 B CN1518558 B CN 1518558B CN 018225993 A CN018225993 A CN 018225993A CN 01822599 A CN01822599 A CN 01822599A CN 1518558 B CN1518558 B CN 1518558B
Authority
CN
China
Prior art keywords
peptide
pro
protein
pharmaceutical composition
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN018225993A
Other languages
English (en)
Chinese (zh)
Other versions
CN1518558A (zh
Inventor
P·佩策尔保尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrex Medical Research and Development GmbH
Original Assignee
Fibrex Medical Research and Development GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Research and Development GmbH filed Critical Fibrex Medical Research and Development GmbH
Publication of CN1518558A publication Critical patent/CN1518558A/zh
Application granted granted Critical
Publication of CN1518558B publication Critical patent/CN1518558B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN018225993A 2000-12-12 2001-12-07 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途 Expired - Fee Related CN1518558B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA2063/2000 2000-12-12
AT20632000 2000-12-12
PCT/AT2001/000387 WO2002048180A2 (de) 2000-12-12 2001-12-07 Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910163553A Division CN101676299A (zh) 2000-12-12 2001-12-07 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途

Publications (2)

Publication Number Publication Date
CN1518558A CN1518558A (zh) 2004-08-04
CN1518558B true CN1518558B (zh) 2010-06-16

Family

ID=3689750

Family Applications (2)

Application Number Title Priority Date Filing Date
CN018225993A Expired - Fee Related CN1518558B (zh) 2000-12-12 2001-12-07 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
CN200910163553A Pending CN101676299A (zh) 2000-12-12 2001-12-07 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910163553A Pending CN101676299A (zh) 2000-12-12 2001-12-07 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途

Country Status (30)

Country Link
US (4) US7271144B2 (enExample)
EP (2) EP1341819B1 (enExample)
JP (1) JP4181874B2 (enExample)
KR (1) KR100864069B1 (enExample)
CN (2) CN1518558B (enExample)
AT (2) ATE329614T1 (enExample)
AU (1) AU2002221316A1 (enExample)
BG (1) BG107891A (enExample)
BR (1) BR0116122A (enExample)
CA (1) CA2430972C (enExample)
CY (2) CY1106108T1 (enExample)
CZ (1) CZ20031630A3 (enExample)
DE (2) DE50114771D1 (enExample)
DK (2) DK1586586T3 (enExample)
EA (1) EA005576B1 (enExample)
EE (1) EE200300283A (enExample)
ES (2) ES2323963T3 (enExample)
HR (1) HRP20030564A2 (enExample)
HU (1) HUP0401536A3 (enExample)
IL (2) IL156360A0 (enExample)
MX (1) MXPA03005218A (enExample)
NO (1) NO330767B1 (enExample)
NZ (1) NZ550619A (enExample)
PL (2) PL209419B1 (enExample)
PT (2) PT1341819E (enExample)
SI (2) SI1586586T1 (enExample)
SK (1) SK7062003A3 (enExample)
WO (1) WO2002048180A2 (enExample)
YU (1) YU53803A (enExample)
ZA (1) ZA200304545B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430972C (en) 2000-12-12 2014-08-05 Fibrex Medical Research & Development Gmbh Fibrin fragments for treating inflammation
WO2006000007A1 (de) * 2004-06-25 2006-01-05 Fibrex Medical Research & Development Gesmbh Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
FR2879604B1 (fr) * 2004-12-22 2010-08-13 Biomerieux Sa Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations
AT502987A1 (de) 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
CN101389653A (zh) 2006-02-23 2009-03-18 菲布雷克斯医疗研究及开发有限责任公司 肽和肽衍生物以及含有它们的药物组合物
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
EP1987063B1 (en) * 2006-02-23 2009-09-23 Fibrex Medical Research & Development GmbH Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
FR2900657B1 (fr) * 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
WO2009038729A2 (en) 2007-09-17 2009-03-26 Regenerx Biopharmaceuticals, Inc. Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen
FR2908134B1 (fr) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
WO2009096502A1 (ja) * 2008-01-31 2009-08-06 Japan As Represented By President Of National Center Of Neurology And Psychiatry うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8088890B2 (en) 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
US20100152832A1 (en) * 2008-12-12 2010-06-17 Medtronic Vascular, Inc. Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US12171802B2 (en) 2016-06-02 2024-12-24 University Of Maryland, Baltimore Compositions for inhibiting fibrin-VLDL receptor-dependent inflammation and methods of treatment
EP3912679A1 (en) * 2020-05-19 2021-11-24 Johann Wolfgang Goethe-Universität Frankfurt am Main Bbeta-15-42 for the treatment of viral endothelitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927916A (en) * 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
FR2795735B1 (fr) * 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
CA2430972C (en) * 2000-12-12 2014-08-05 Fibrex Medical Research & Development Gmbh Fibrin fragments for treating inflammation
US7201763B2 (en) * 2001-10-24 2007-04-10 Boston Scientific Scimed, Inc. Distal balloon waist material relief and method of manufacture

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SKOGEN W F等.Fibrinogen-Derived Petide Bβ1-42 Isa Multidomained Neutrophil Chemoattractant.Blood71 5.1988,摘要、图4以及第1478页右栏第12-13行和最后一段.
SKOGEN W F等.Fibrinogen-Derived Petide Bβ1-42 Isa Multidomained Neutrophil Chemoattractant.Blood71 5.1988,摘要、图4以及第1478页右栏第12-13行和最后一段. *

Also Published As

Publication number Publication date
DK1341819T3 (da) 2006-10-16
CA2430972C (en) 2014-08-05
NO20032656D0 (no) 2003-06-12
EA200300678A1 (ru) 2003-10-30
ATE329614T1 (de) 2006-07-15
EP1586586A2 (de) 2005-10-19
JP4181874B2 (ja) 2008-11-19
US20090137464A1 (en) 2009-05-28
AU2002221316A1 (en) 2002-06-24
CN101676299A (zh) 2010-03-24
HUP0401536A3 (en) 2008-09-29
SI1586586T1 (sl) 2009-08-31
PL362924A1 (en) 2004-11-02
SK7062003A3 (en) 2003-11-04
ES2323963T3 (es) 2009-07-28
MXPA03005218A (es) 2004-12-03
EP1586586B1 (de) 2009-03-11
EP1341819B1 (de) 2006-06-14
EA005576B1 (ru) 2005-04-28
CA2430972A1 (en) 2002-06-20
KR20030060988A (ko) 2003-07-16
ATE425184T1 (de) 2009-03-15
ES2266093T3 (es) 2007-03-01
PL209419B1 (pl) 2011-08-31
US20090088384A1 (en) 2009-04-02
BG107891A (bg) 2004-08-31
CN1518558A (zh) 2004-08-04
JP2004527469A (ja) 2004-09-09
ZA200304545B (en) 2004-09-13
IL156360A0 (en) 2004-01-04
PL209752B1 (pl) 2011-10-31
US8067373B2 (en) 2011-11-29
HK1084400A1 (zh) 2006-07-28
NZ550619A (en) 2008-06-30
US20040192596A1 (en) 2004-09-30
EE200300283A (et) 2003-10-15
EP1586586A3 (de) 2006-03-29
PT1586586E (pt) 2010-05-28
WO2002048180A3 (de) 2003-01-30
WO2002048180A2 (de) 2002-06-20
CY1106108T1 (el) 2011-06-08
EP1341819A2 (de) 2003-09-10
HRP20030564A2 (en) 2005-06-30
US20070037749A1 (en) 2007-02-15
US7494973B2 (en) 2009-02-24
SI1341819T1 (sl) 2006-10-31
US7811985B2 (en) 2010-10-12
NO330767B1 (no) 2011-07-11
US7271144B2 (en) 2007-09-18
DE50110182D1 (de) 2006-07-27
BR0116122A (pt) 2003-10-14
YU53803A (sh) 2006-03-03
DK1586586T3 (da) 2009-06-29
IL156360A (en) 2012-12-31
CY1109107T1 (el) 2014-07-02
CZ20031630A3 (cs) 2003-10-15
NO20032656L (no) 2003-06-12
KR100864069B1 (ko) 2008-10-16
HUP0401536A2 (hu) 2004-11-29
PT1341819E (pt) 2006-10-31
DE50114771D1 (de) 2009-04-23

Similar Documents

Publication Publication Date Title
CN1518558B (zh) 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
EP0656008B1 (en) Thrombin receptor antagonists
AU2002233082B2 (en) Long lasting growth hormone releasing factor derivatives
EP0478101B1 (en) Therapeutic use of peptides having thrombospondin-like activity
IE57880B1 (en) Novel atrial peptide
EP0298820A1 (fr) Nouveaux dérivés peptidiques et leur application notamment en thérapeutique
JPH03118331A (ja) 環状フイブリノーゲンレセプター拮抗薬
EP0410767A1 (en) Fibrinogen receptor antagonists
JP2004527469A6 (ja) ペプチドおよび／またはタンパク質、並びにその治療用および／または予防用医薬成分を調製するための使用
US5814610A (en) Osteogenic growth oligopeptides and pharmaceutical compositions containing them
EP0514721B1 (en) Peptides having thrombospondin-like activity and their therapeutic use
US6339062B1 (en) Retroinverso polypeptides that mimic or inhibit thrombospondin activity
AU630132B2 (en) Anticoagulant peptides
US5587457A (en) Neutrophil stimulating peptides
AU2006301494B2 (en) Antagonists against interaction of PF4 and RANTES
SK130094A3 (en) Linear peptides, method of their production, pharmaceutical preparation on their base and method of their production
US5232912A (en) Anticoagulant peptides
WO1993006128A1 (en) Tnf antagonist peptides
HK1140212A (en) Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic pharmaceutical
JPH08512310A (ja) ペプチド化合物
JPH07278191A (ja) 新規ペプチドもしくは蛋白質及びそれを探索する方法
HK1084400B (en) Peptide and/or proteins and their use for the manufacture of a therapeutic and/or preventive medicament
JPH0641193A (ja) ペプチド誘導体およびその用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100616

Termination date: 20161207